the talent pool is undeniable, just a matter if and when they can put something together. The Medical cancer device field is exploding, so hopefully they bring something to this public Market soon.
991k outstanding now. lets hope this is the year.....
Company info
Dianwen Ju , Ph.D. has served as our President, Chief Executive Officer and sole Director since April 25, 2011. He received a Ph.D. degree in Immunology in 1999, a Master’s degree in Pharmacology in 1994, and a Bachelor’s degree in Pharmacy in 1991 in Second Military Medical University, Shanghai, China. He joined Shanghai MediPharm Biotech in 2002 as a director of R&D and he is currently CEO and Chairman of MediPharm Biotech Pharmaceuticals Co. Ltd (Bermuda). He is also a Research Professor in Fudan University, Shanghai, China. He has 20 years of R&D experiences in biological drugs and new therapies for the treatment of malignant cancer. He has more than 40 publications in peer-reviewed international journals including Journal of Clinical Oncology, Cancer Research, Gene Therapy, International Journal of Oncology, Cancer Gene Therapy, Cancer Immunology & Immunotherapy, et al. He has invented 15 biotechnologies of which 8 are patented and the remaining 7 are pending. Before joining MediPharm in 2002, Dr. Ju had been an assistant director and a senior scientist in Shanghai Brilliance Biotech Institute and a lecturer in Immunology in Second Military Medical University for 6 years. Mr. Ju brings to our Board a wealth of experience derived from his services in various businesses. He has demonstrated strong acumen and ability to exercise sound judgment and has a reputation for integrity, honesty and adherence to ethical standards.
Jimmy Wang has served as our Treasurer since April 25, 2011. He is the Chief Financial Officer of American Compass, Inc., where he has served, initially as Chief Accounting Officer, since 2003. Prior to joining American Compass, Inc., he served as an accounting manager for Planned Parenthood of the Greater Miami Valley from 2000 to 2003. He has served as a Director for Nevada Gold Holdings, Inc. since January 25, 2011. He is a graduate of the City University of New York, where he majored in both Accounting & Information Systems and Economics.
Xiao Chen has served as our Chief Financial Officer since April 25, 2011. He worked at Brilliance China Group from 1994 to 2001. From 2005 to 2008, he worked as director of finance at Shanghai Medipharm Co. Ltd. Since 2008, Mr. Chen has been working at Hybrid Kinetic Group Limited as vice general manager of investments in China. Mr. Chen holds a bachelor’s degree in investment management from Shanghai Finance University.
Guofeng Xu has served as our Secretary since November 21, 2011. He performed Ph.D. Research involving the identification of new metalloprotease genes at the University of Virginia in Charlottesville, Virginia from August 2004 until December 2011. From August 2001 until June 2004 he performed M.S. Research in Shanghai, China involving the anti-cancer drug Onconase. Mr. Xu received a Ph.D. in Cell Biology from the University of Virginia in 2011 and a B.D. in Biological Science and Technologies from Zhejiang University in Hangzhou China in 2001.
